Can Thrombelastography Predict Blood Loss in Patients With Hip Fractures

Completed

• Conditions: Hip Fracture; Blood Loss
• Interventions: Biological: Thrombelastography analysis (TEG)

• Registration Number: NCT02297061
• Lead Sponsor: Hvidovre University Hospital

Brief Summary

Hip fractures are associated with a large hidden blood loss. That is, the total blood loss associated with hip fracture surgery is much greater than that observed intra operatively. There is currently no viable method of identifying patients at risk of transfusion. The on admission haemoglobin level has been shown to be falsely reassuring .

We are conducting a study of 200 consecutive hip fracture patients. Thrombelastography (TEG) is taken on admission. The results are blinded to clinicians. Results will be evaluated at the end of the study, comparing intra-operative and total blood losses with the TEG profile of the patient.

Detailed Description

Hip fractures are associated with a large hidden blood loss. That is, the total blood loss associated with hip fracture surgery is much greater than that observed intra operatively. The total blood loss depends on the type of fracture and associated surgery. Extra-capsular fractures treated with an intramedullary nail are thus associated with the largest hidden blood loss with a median of approximately 1500 ml . This hidden blood loss is primarily associated with the trauma and fracture itself and not, as such, with the surgical procedure.

Postoperative anaemia necessitating transfusion and a haemoglobin level below 8 g per dL, in hip fracture patients, are both associated with an increased mortality Controversy remains on the benefits and indications for transfusion in this group of patients.

There is currently no viable method of identifying patients at risk of transfusion. The on admission haemoglobin level has been shown to be falsely reassuring . TEG has to our knowledge only been used in one previous study of hip fractures. The outcome measure in this study was thromboembolic events. We have not been able to identify any studies on the use of TEG, INR, APTT or other tests as predictors of blood loss in hip fracture patients.

Clinicians would greatly benefit from a tool to predict the at-risk patient on admission. TEG has been suggested as such a tool. Bolliger et al suggests that TEG can be used in goal-oriented algorithms to optimize targeted transfusion therapies in trauma patients or patients undergoing major surgery. We hypothesize that TEG can be used for this purpose in patients with hip fracture. These patients can have large blood losses and they sustain the double trauma of a hip fracture and major orthopaedic surgery.

Study Timeline

• Study Start: 2013-12
• Study First Submitted: 2014-02-09
• Primary Completion: 2014-05
• Study Completion: 2014-08
• Status Verified: 2014-11
• Study First Submitted QC: 2014-11-18
• Last Update Submitted: 2014-11-18
• Study First Posted: 2014-11-21
• Last Update Posted: 2014-11-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 180

Inclusion Criteria

• All hip fracture patients admitted through the emergency room (ER) at Hvidovre University Hospital in the study period.

Exclusion Criteria

• Hip fracture patients who are transfered from other wards in the hospital do not go through the ER and are not included.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
TEG group	Thrombelastography analysis (TEG)	200 consecutive hip fracture patients, Thrombelastography is performed on admission.

Primary Outcome Measures

Name	Time	Method
Total blood loss compared to TEG profile on admission	4 days postoperatively	TEG profiles will be compared to the blood losses of the patients, after completion of the study.

Secondary Outcome Measures

Name	Time	Method
Thrombotic incidences	90 days after operation	Can TEG analysis predict thrombotic incidences in hip fracture patients.
Mortality	90 days after operation	Relation between TEG values and mortality.

Trial Locations

Locations (1)

Hvidovre University Hospital; 🇩🇰 Hvidovre, Denmark